{
    "name": "ecallantide",
    "comment": "Rx",
    "other_names": [
        "Kalbitor"
    ],
    "classes": [
        "Immunomodulators",
        "Kallikrein Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/kalbitor-ecallantide-999410",
    "pregnancy": {
        "common": [
            "Available data have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Increased early fetal deaths resulting in decreased live fetuses were observed in rats following treatment during organogenesis with IV dose ~1.6x the maximum recommended human dose (MRHD) in the presence of maternal toxicity",
                    "No effects present on embryofetal survival or structural abnormalities in rats and rabbits following treatment during organogenesis with IV doses up to ~1.1 and 6x the MRHD, respectively, or rats treated with SC doses up to 2.4x the MRHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on presence in human milk, effects on breastfed infants, effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Anaphylaxis",
                    "description": [
                        "Anaphylaxis has been reported ",
                        "Administer by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema",
                        "Be aware of similar symptoms between hypersensitivity reactions and hereditary angioedema and closely monitor",
                        "Do not administer to patients with known clinical hypersensitivity to ecallantide"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Risk of potentially serious hypersensitivity reactions, including anaphylaxis; observe patients for an appropriate period of time after administration; do not administer to patients with known hypersensitivity to ecallantide (see Contraindications and Black Box Warnings)"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "ecallantide, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "ecallantide, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "ecallantide, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "ecallantide, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "ecallantide, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "ecallantide, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "ecallantide and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and ecallantide both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "16.1"
        },
        {
            "name": "Nausea",
            "percent": "12.9"
        },
        {
            "name": "Fatigue",
            "percent": "11.8"
        },
        {
            "name": "Diarrhea",
            "percent": "10.6"
        },
        {
            "name": "Upper respiratory tract infection",
            "percent": "8.2"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "5.9"
        },
        {
            "name": "Vomiting",
            "percent": "5.5"
        },
        {
            "name": "Pruritus",
            "percent": "5.1"
        },
        {
            "name": "Upper abdominal pain",
            "percent": "5.1"
        },
        {
            "name": "Pyrexia",
            "percent": "4.7"
        },
        {
            "name": "Anaphylaxis",
            "percent": "3.9"
        },
        {
            "name": "Injection site reactions",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        }
    ]
}